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Abstract 
 
Background and Purpose Patients with non-valvular atrial fibrillation are often denied oral 
anticoagulation due to falls risk. The latter is variably defined and existing studies have not 
compared the associated risk of bleeding with other cardiovascular events. There are no data 
regarding outcomes in individuals with non-valvular atrial fibrillation with a prior history of 
(actual) falls, rather than being ‘at risk of falls’.  Our objective was to evaluate the risk of 
cardiovascular outcomes associated with prior history of falls in patients with atrial 
fibrillation in a contemporary ‘real world’ cohort. 
Methods  Patients with non-valvular atrial fibrillation in a four-hospital-institution 
between 2000 and 2010 were included. Stroke/thromboembolism event rates were calculated 
according to prior history of falls. Risk factors were investigated by Cox regression.  
Results  Among 7156 atrial fibrillation patients, prior history of falls/trauma was 
uncommon (n=76; 1.1%) and compared with patients without history of falls, those patients 
were older, less likely to be on oral anticoagulation and had higher risk scores for 
stroke/thromboembolism, but not for bleeding.  
Compared with no prior history of falls, rates of stroke/thromboembolism (p=0.01) and all-
cause mortality (p<0.0001) were significantly higher in patients with previous falls.  
In multivariable analyses, prior history of falls was independently associated with 
stroke/thromboembolism (hazard ratio, HR 5.19, 95% CI 2.1-12.6;p<0.0001), major bleeding 
(HR 4.01, 1.49-10.8;p=0.006) and all-cause mortality (HR 3.69, 1.52-8.95; p=0.04), but not 
haemorrhagic stroke (HR 4.20, 0.58-30.48; p=0.16) in patients on oral anticoagulation.   
Conclusion    In this large ‘real world’ atrial fibrillation cohort, prior history of falls was 
uncommon, but independently increased risk of stroke/thromboembolism, bleeding and 
mortality, but not haemorrhagic stroke in the presence of anticoagulation. Prior history of 
(actual) falls may be a more clinically useful risk prognosticator than “being at risk of falls”.  
 
Key words: atrial fibrillation; falls; stroke; thromboembolism; bleeding 
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Abbreviations and Acronyms 
 
CHADS2 Acronym for Congestive heart failure, Hypertension, Age ≥75 
years, Diabetes, previous Stroke 
CHA2DS2-VASc Acronym for Congestive heart failure, Hypertension, Age ≥75 
years, Diabetes, previous Stroke, Vascular disease, Age 65-74 
years, Sex category (female) 
HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding 
history or predisposition, Labile international normalized ratio, 
Elderly (> 65 years), Drugs/alcohol concomitantly 
VKA Vitamin K antagonist 
NOAC Non-VKA Oral Anticoagulants (previously referred to as new 
or novel oral anticoagulants) 
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Introduction 
 
The global burden of non-valvular atrial fibrillation and ischaemic stroke/thromboembolism 
is unquestionable(1-3). Oral anticoagulation, most commonly with the vitamin K antagonists 
(VKA, e.g. warfarin), but also with non-VKA oral anticoagulants (NOACs)(4,5), confers a 
well-established prognostic benefit for prevention of ischaemic stroke/thromboembolism in 
the setting of atrial fibrillation.  
 
All oral anticoagulants also confer a risk of bleeding(6), but even in patients with high levels 
of comorbidity, the net clinical benefit is still in favour of oral anticoagulation(7,8), and the 
same is probably true for NOACs(5). Therefore, oral anticoagulation is recommended in all 
individuals with atrial fibrillation other than those who are at truly low-risk of ischaemic 
stroke/thromboembolism(9).  However, despite improved clinical risk prediction tools for 
risk stratification of ischaemic stroke/thromboembolism and bleeding and consensus 
guideline recommendations(10,11), levels of oral anticoagulation are still suboptimal in 
clinical practice, especially in the elderly(12).  
  
One of the commonest reasons for not giving oral anticoagulation is a perceived risk of 
falls(13-17). Falls are a significant cause of morbidity and mortality, particularly in older 
populations, and incur high costs to individuals and health systems(18). Of note, the aetiology 
of falls is multi-factorial(19,20). AF itself is an independent predictor of falls(21,22). In the 
setting of atrial fibrillation, the main focus of the physician’s concern regarding falls is the 
increased predisposition to major bleeding if oral anticoagulation is initiated(14,15). 
However, patients on oral anticoagulation at high risk of falls do not necessarily have a 
significantly increased risk of major bleeds(23), suggesting that being at risk of falls is not a 
contraindication to oral anticoagulation. Even studies which have shown a high rate of 
intracranial haemorrhage in atrial fibrillation patients with high risk of falls suggest that there 
is still an overall benefit of oral anticoagulation due to prevention of ischaemic stroke(24).  
 
Some studies have considered patients with AF at increased risk of falls but with varying 
definitions and in different subpopulations(21-27). A previous history of (actual) falls is 
probably the strongest risk factor for future falls, but the risk of cardiovascular events 
associated with previous history of falls has not been compared with risk of major bleeding in 
atrial fibrillation patients.  
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In the first contemporary study of its kind, our objective was to evaluate the risk of bleeding 
and cardiovascular outcomes associated with a prior history of (actual) falls - rather than 
‘being at risk of falls’ per se - in a large, “real- world” cohort of individuals with atrial 
fibrillation. We tested the hypothesis that prior history of falls would have an impact on 
ischaemic stroke/thromboembolism, bleeding and mortality in patients with atrial fibrillation. 
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Methods 
 
Study population 
The methods of the Loire Valley Atrial Fibrillation Project, which is based at the Centre 
Hospitalier Régional et Universitaire in Tours (France), have been previously reported(28). 
The institution includes four hospitals covering all medical and surgical specialties, and is the 
only public institution in an area of around 4,000 km², serving approximately 400,000 
inhabitants. All patients diagnosed with atrial fibrillation or atrial flutter by the cardiology 
department between 2000-2010 were identified(28), excluding patients with valvular atrial 
fibrillation. Patients were followed from the first record of atrial fibrillation after 1 January 
2000 (i.e. index date) up to the latest data collection at the time of study (December 2010). 
Treatment at discharge was obtained by screening hospitalisation reports, and information on 
comorbidities was obtained from the computerised coding system.  
 
Prior history of falls was ascertained from clinical history or medical records. For each 
patient, the CHADS2(10) and CHA2DS2-VASc(11) scores were calculated. The CHADS2 
score was the sum of points obtained after adding one point for congestive heart failure, 
hypertension, age ≥75, and diabetes, and two points for previous stroke or 
thromboembolism(11). The CHA2DS2-VASc score was the sum of points after adding one 
point for congestive heart failure, hypertension, diabetes, vascular disease (including history 
of coronary, cerebrovascular or peripheral vascular disease), age 65-74, and female gender, 
and two points for previous stroke or thromboembolism and age ≥75(11). According to the 
two risk scores, patients with a score of 0 on either schema were considered as ‘low risk’, 1 
as ‘intermediate risk’, and ≥2 as ‘high risk’ of stroke and thromboembolism. 
 
The HAS-BLED (Hypertension, Abnormal renal and/or liver function, Stroke, Bleeding 
history or predisposition, Labile International Normalized Ratio (INR), Elderly (> 65 years), 
Drugs (antiplatelet drugs or NSAIDS)/alcohol excess concomitantly) score is a validated 
scoring system for bleeding risk stratification in AF patients(29). For each patient, the HAS-
BLED score was also calculated as the sum of the points obtained after adding one point for 
the presence of each individual factor). Patients with HAS-BLED score of 0-2 were deemed 
to have ‘low’ bleeding risk and those with HAS-BLED score of ≥3 were classified as ‘high’ 
bleeding risk. 
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During follow-up, information on outcomes of thromboembolism, stroke (ischaemic or 
haemorrhagic), major bleeding, and all-cause mortality were recorded. Major bleeding was 
defined as bleeding with a reduction in the haemoglobin level of at least 2g per litre, or with 
transfusion of at least 1 unit of blood, or symptomatic bleeding in a critical area or organ 
(e.g., intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or 
intramuscular with compartment syndrome) or bleeding that causes death.  All bleeding data 
were identified with the diagnosis coded in a subsequent hospitalization during follow-up – 
thus, we recorded all 'hospitalizations with a bleed' as an additional criterion for major 
bleeding.  
 
Statistical analysis 
Risk factors were investigated by Cox regression. Baseline characteristics were determined 
based on prior history of falls and differences were investigated using chi-squared test for 
categorical covariates and Kruskal-Wallis test for continuous covariates.  
 
Event rates of ischaemic stroke/thromboembolism, bleeding and all-cause mortality were 
calculated for all patients by prior history of falls, stratifying by presence or absence of VKA 
therapy. Haemorrhagic strokes were excluded from analyses of “ischaemic stroke” or 
“ischaemic stroke/thromboembolism”. Event rates were also calculated by age and sex 
categories. The risk associated with prior history of falls was estimated in Cox proportional-
hazard models. Both univariate and multivariate (including all the CHA2DS2-VASc risk 
factors) Cox regression models were applied.  A two-sided p-value <0.05 was considered 
statistically significant. All analyses were performed with SPSS statistical software version 
18.0 (IBM, USA). 
 
Ethics approval 
The study was approved by the local ethical board of our institution (Pôle Cœur Thorax 
Vasculaire, Centre Hospitalier Universitaire Trousseau, Tours, France). The informed 
consent of patients was deemed unnecessary for our analyses since this is a retrospective 
analysis of a single centre cardiology department.  
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Results 
 
From the whole cohort, 7156 patients with nonvalvular atrial fibrillation were included in the 
analyses. Baseline characteristics are displayed in Table 1. Prior history of falls was 
uncommon (76/7156=1.1%). Patients with prior history of falls were older (p<0.0001), and 
after age-adjustment, were more likely to be diabetic (p=0.009), have coronary artery disease 
(p=0.04) and take ACE-inhibitors (p=0.04) and anti-arrhythmic agents (p=0.03). Patients 
with prior history of falls were less likely to take vitamin K antagonists (p<0.0001) and 
antithrombotic agents (p=0.002) and had higher CHADS2 (p=0.001) and CHA2DS2VASc 
scores (p=0.02). HAS-BLED scores did not significantly differ by history of falls (p=0.19). 
 
Of the cohort, 3607/7156 (50.4%) of all patients but only 24.3% (17/76) of patients with prior 
history of falls were on VKA. Event rates for ischaemic stroke (p=0.01), ischaemic 
stroke/thromboembolism (p=0.01) and all-cause mortality (p<0.0001) were significantly 
higher in patients with prior history of falls, but not rates of bleeding (p=0.38) and 
haemorrhagic stroke (p=0.09) (Table 2). In individuals with history of falls, the event rates 
per 100 person-years were 1.18 (0.54,2.25) for ischaemic stroke, 1.58(0.82,2.76) for 
ischaemic stroke/thromboembolism, 0.39(0.08,1.15) for haemorrhagic stroke, 1.05(0.45,2.07) 
for bleeding and 2.63(1.61,4.06) for all-cause mortality.   
 
Sensitivity analysis 
Regardless of history of falls, there were no significant differences between anticoagulated 
and non-anticoagulated individuals for event rates for ischaemic stroke, ischaemic 
stroke/thromboembolism, all-cause mortality, bleeding or haemorrhagic stroke (Table 3).  
 
Multivariable analysis 
Cox regression analyses for all AF patients with HF are presented in Table 4. On univariable 
analyses in patients overall, prior history of falls significantly increased the risk of ischaemic 
stroke/thromboembolism (hazard ratio, HR 2.75, 1.55-4.88; p=0.001), haemorrhagic stroke 
(HR 3.79, 1.20-12.00; p=0.02), bleeding (HR 1.86, 1.08-3.23; p=0.026) and all-cause 
mortality (HR 2.74, 1.75-4.27; p<0.0001). On multivariable analysis, only the associations 
for ischaemic stroke/thromboembolism (HR 1.71, 1.04-2.83; p=0.04) and all-cause mortality 
(HR 1.68, 1.07-2.62; p=0.02) remained significant.  
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In anticoagulated individuals, prior history of falls was associated with increased risk of 
ischaemic stroke/thromboembolism (HR 5.18, 2.13-12.61; p<0.0001), bleeding (HR 3.70, 
1.38-9.97; p=0.01) and all-cause mortality (HR 3.91, 1.61-9.51; p=0.003) in multivariate 
analyses, but not haemorrhagic stroke (HR 4.36, 0.60-31.83; p=0.15). In non-anticoagulated 
individuals, there was no independent association between prior history of falls and 
ischaemic stroke/thromboembolism, bleeding, haemorrhagic stroke or all-cause mortality.  
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Discussion 
 
In the first study of bleeding and cardiovascular outcomes in patients with history of falls and 
in this large ‘real world’ atrial fibrillation cohort, our principal findings are as follows: (i) 
prior history of falls was uncommon, but independently increased risk of ischaemic 
stroke/thromboembolism by five-fold, and of bleeding and mortality by nearly four-fold, in 
the presence of anticoagulation; and (ii) the risk of haemorrhagic stroke was not increased in 
anticoagulated individuals. 
 
In a US cohort of Medicare-treated individuals(24), 1245/18261 (6.8%) were at high risk of 
falls, compared to the 1.1% of our study population with prior history of falls. The rate of 
intracranial haemorrhage per 100 patient-years in that study was 2.8 (1.9-4.1) in patients at 
high risk for falls and 1.1 (1.0-1.3) in other patients(24). In another US study of patients on 
anticoagulation for any indication, the incidence per 100 patient-years of major bleeding was 
8.0 in patients at high risk of falls versus 6.8 in those at low risk of falls(23). Interestingly, the 
incidence of major bleeding directly after a fall was only 0.6 per 100 patient-years. We 
observed lower event rates in our population. 
 
The increased risk of ischaemic stroke/thromboembolism and all-cause mortality in 
anticoagulated patients with history of falls probably reflects increased comorbidities and 
higher baseline risk stratification scores (e.g. CHA2DS2-VASc), compared with patients with 
no history of falls, rather than any association between falls and ischaemic 
stroke/thromboembolism per se. In individuals not on anticoagulation, there was no 
independent association between history of falls and ischaemic stroke/thromboembolism, 
bleeding (including haemorrhagic stroke) or mortality, suggesting that other comorbidities 
were more important in influencing outcomes (i.e. CHA2DS2-VASc risk factors). 
 
In our study population, only 24.3% of patients with history of falls were on VKA therapy, 
compared with 55.9% of patients without history of falls. This proportion of anticoagulated 
individuals is much lower than other studies(24,25), but is consistent with the well-documented 
reluctance of healthcare professionals to prescribe VKA in the context of risk of falls(14-16). 
Surprisingly, in our study population, there was no statistically significant difference in event 
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rates for ischaemic stroke/thromboembolism or mortality between anticoagulated and non-
anticoagulated individuals, regardless of history of falls.  
 
Although history of falls increased the risk of major bleeding in anticoagulated individuals, 
there was no associated increased risk of haemorrhagic stroke. This is consistent with a 
Markov decision analysis, which estimated that individuals taking warfarin must fall 295 
times in one year in order for the benefits of warfarin therapy to be outweighed by the risk of 
intracranial haemorrhage(26).  
    
Study limitations. 
This study is based on a ‘real world’ registry with inherent limitations of diagnostic coding 
and case ascertainment, as previously reported(28). Despite stratification and adjustment for 
several risk factors, the non-randomized design leaves a risk of residual confounding factors. 
If a resident moved away from the area or died or had a stroke diagnosed elsewhere, 
information on the event was not available. However, the relatively high number of deaths in 
our study suggests a high proportion of ascertainment of events. The study population was 
hospital-based and therefore may not be representative of all patients with AF, many of 
whom are not hospitalized for their arrhythmia. The study was not ethnically diverse and our 
findings may not be generalisable to other populations.  
 
The data regarding oral anticoagulation use are only regarding baseline therapy and do not 
reflect any changes in prescribed therapy or adherence to therapy. Also, data regarding the 
“time in therapeutic range” are not available for our study population. Our study population 
was a prospective cohort design and not a randomised clinical trial, therefore, confounding by 
indication is a possibility(30). However, the effect of this confounding is likely to be minimal 
since the individuals at highest risk of study outcomes (based on risk prediction scores) were 
least likely to be taking oral anticoagulation.  
 
Conclusions 
In this large ‘real world’ atrial fibrillation cohort, prior history of falls was uncommon, but 
independently increased risk of ischaemic stroke/thromboembolism, bleeding and mortality, 
but not haemorrhagic stroke in the presence of anticoagulation. Prior history of (actual) falls 
may be a more clinically useful risk prognosticator than “being at risk of falls” per se. 
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Table 1: Characteristics of patients with atrial fibrillation by risk of falls  
n (%) 
Prior history of falls 
 
n=76 
No history of falls 
 
           n=7080 
p-value 
Age-
adjusted 
p-value 
Mean age (SD) 82.9(8.9) 69.9(15.1) <0.0001  
Female 43(56.6) 2661(37.6) 0.001 0.23 
Type of AF 
Paroxysmal 
Permanent 
Persistent 
 
48(63.2) 
26(34.2) 
2(2.6) 
 
4128(58.3) 
2578(36.4) 
374(5.3) 
0.49 0.57 
Comorbidities     
Hypertension 40(52.6) 2992(42.3) 0.05 0.41 
Diabetes 19(25.0) 1089(15.4) 0.02 0.009 
Previous stroke 12(15.8) 582(8.2) 0.03 0.08 
Coronary artery disease 17(22.4) 2113(29.8) 0.17 0.04 
Any vascular disease 21(27.6) 2339(33.0) 0.19 0.08 
Heart failure 24(31.6) 3502(49.5) 0.002 0.11 
Renal impairment 12(15.8) 540(7.6) 0.02 0.13 
Liver impairment 0(0) 19(0.3) 0.82 0.99 
Dyslipidaemia 11(14.5) 1352(19.1) 0.19 0.90 
Smoking 5(6.6) 912(12.9) 0.06 0.49 
Pacemaker/ICD 13(17.1) 1141(16.1) 0.76 0.60 
Bleeding risk factors     
Previous bleeding 6(7.9) 323(4.6) 0.16 0.39 
Labile INR 3(3.9) 119(1.7) 0.14 0.10 
Anaemia 0(0) 41(0.6) 0.65 0.98 
NSAIDs 1(1.3) 9(0.1) 0.10 0.10 
Drugs 10(13.2) 1225(17.3) 0.45 0.13 
Cancer (active) 0(0) 119(1.7) 0.64 0.99 
Thrombocytopenia 0(0) 6(0.1) 0.94 0.99 
Antithrombotic agents     
  Vitamin K antagonist 17(24.3) 3590(55.9) <0.001 <0.0001 
  Antiplatelets 33(49.3) 2242(35.7) 0.03 0.31 
  Any antithrombotic  44(65.7) 5089(80.9) 0.003 0.002 
Other medical therapy     
  ACE-I 21(53.8) 1284(38.3) 0.05 0.04 
  Beta-blocker 16(41.0) 1602(47.8) 0.43 0.77 
  Digoxin 10(25.6) 958(28.6) 0.86 0.51 
  Diuretic 22(56.4) 1431(42.7) 0.10 0.65 
  Antiarrhythmic agent 12(29.3) 1914(49.0) 0.01 0.03 
  Calcium channel 
blocker 4(28.6) 289(18.4) 0.31 0.62 
CHADS2 
Mean (s.d.) 2.7(1.3) 1.7(1.3) <0.0001 0.001 
CHA2DS2-VASc  
Mean (s.d.) 4.4(1.6) 3.1(1.8) <0.0001 0.023 
HASBLED  
Mean (s.d.) 2.07(1.03) 1.5(1.08) <0.0001 0.19 
SD: standard deviation; AF: atrial fibrillation; ICD: implantable cardiac defibrillator; INR: international normalised ratio; 
CHADS2 (1 point each for congestive heart failure, hypertension, age ≥75, and diabetes, and 2 points for previous stroke or 
thromboembolism); CHA2DS2-VASc (1 point for congestive heart failure, hypertension, diabetes, vascular disease, age 65-
74, and female sex, and 2 points for previous stroke or thromboembolism and age ≥75); HAS-BLED (Hypertension, 
Abnormal renal and/or liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio 
(INR), Elderly (> 65 years) 
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Table 2.   Event rates (95% confidence interval) per 100 person years by prior history of 
falls 
 
 
*p-value for 2-sided chi-squared test  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior history of falls 
n=76 
No history of falls 
n=7080 
 Events Event rate Events Event rate P* 
Ischaemic  Stroke 9 1.18 (0.54,2.25) 353 0.50(0.45,0.55) 0.01 
Ischaemic stroke/TE 12 1.58 (0.82,2.76) 533 0.75(0.68,0.83) 0.01 
Haemorrhagic stroke 3 0.39(0.08,1.15) 98 0.14(0.11-0.17) 0.09 
Bleeding 8 1.05 (0.45,2.07) 542 0.77(0.70,0.83) 0.38 
All-cause mortality 20 2.63 (1.61,4.06) 827 1.17(1.07,1.27) <0.0001 
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Table 3. Event rates (95% confidence interval) per 100 person years by prior history of falls stratified by anticoagulation status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†p-value for 2-sided chi-squared test comparing anticoagulated and non-anticoagulated individuals 
 
 
 
 
 Prior history of falls  No history of falls  
 No VKA (n=59) VKA (n=17)    p† No VKA (n=3490) VKA (n=3590) p† 
 Events Event rate Events Event rate Events Event rate Events Event rate 
Ischaemic  Stroke 3 0.51 (0.1,1.49) 5 2.94 (0.95,6.86) 0.08 151 0.43 (0.37,0.51) 170 0.47 (0.41,0.55) 0.30 
Ischaemic Stroke/TE 6 1.02 (0.37,2.21) 5 2.94 (0.95,6.86) 0.12 218 0.62 (0.54,0.71) 267 0.74 (0.66,0.84) 0.70 
Ischaemic Stroke/TE/All-cause 
mortality 
18 3.05 (1.81,4.82) 8 4.71 (2.03,9.27) 0.39 518 1.47 (1.28,1.69) 509 1.42 (1.30,1.55) 0.88 
Haemorrhagic stroke 2 0.34 (0.04,1.22) 1 0.59 (0.01,3.28) 0.99 34 0.10 (0.07,0.14) 59 0.16 (0.13,0.21) 0.14 
Bleeding 4 0.68 (0.18,1.74) 4 2.35 (0.64,6.02) 0.09 172 0.49 (0.42,0.57) 323 0.9 (0.8,1.00) 0.10 
All-cause mortality 14 2.37 (1.3,3.98) 5 2.94 (0.95,6.86) 0.99 339 0.97 (0.87,1.08) 376 1.05 (0.94,1.16) 0.79 
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Table 4. Cox regression analyses for event rates in patients with prior history of falls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*adjusted for CHA2DS2-VASc 
 
**
 adjusted for CHA2DS2-VASc and HAS-BLED 
 
 
 
 
Ischaemic stroke and 
thromboembolism 
Haemorrhagic stroke Bleeding All-cause mortality 
Prior history of 
falls 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Overall 
Univariate 
Multivariate* 
Multivariate** 
 
2.75(1.55-4.88); p=0.001 
1.71(1.04-2.83); p=0.04 
1.71(1.04-2.83); p=0.04 
 
3.79(1.20-12.00);p=0.02 
2.82(0.88-9.04);p=0.08 
2.92(0.91-9.37);p=0.07 
 
1.86(1.08-3.23);p=0.026 
1.48(0.85-2.57); p=0.16 
1.49(0.86-2.58);p=0.16 
 
2.74(1.75-4.27);p<0.0001 
1.67(1.07-2.62);p=0.03 
1.68(1.07-2.62);p=0.02 
 On OAC 
Univariate 
Multivariate* 
Multivariate** 
 
5.16(2.31-13.63);p<0.0001 
5.19(2.1-12.6);p<0.0001 
5.18(2.13-12.61);p<0.0001 
 
4.76(0.66-34.51);p=0.12 
4.20(0.58-30.48); p=0.16 
4.36(0.60-31.83);p=0.15 
 
3.79(1.41-10.19);p=0.008 
3.32(1.23-8.91);p=0.02 
3.70(1.38-9.97);p=0.01 
 
4.36(1.80-10.57);p=0.001 
3.69(1.52-8.95); p=0.04 
3.91(1.61-9.51);p=0.003 
No OAC 
Univariate 
Multivariate* 
Multivariate** 
 
1.74(0.77-3.91);p=0.18 
0.88(0.38-2.01); p=0.75 
0.88(0.38-2.01);p=0.75 
 
3.97(0.95-16.65);p=0.06 
3.26(0.75-14.15); p=0.12 
3.52(0.81-15.32); p=0.09 
 
1.44(0.54-3.89);p=0.47 
1.08(0.40-2.95);p=0.88 
1.15(0.42-3.14);p=0.79 
 
2.19(1.28-3.73);p=0.04 
1.28(0.74-2.21);p=0.37 
1.27(0.74-2.19);p=0.39 
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Clinical significance 
 
• Patients with non-valvular atrial fibrillation (NVAF) are often denied oral 
anticoagulation (OAC) due to falls risk.    
• Among 7156 NVAF patients, prior history of falls/trauma was uncommon (1.1%), but 
independently increased risk of stroke/TE, bleeding and mortality, but not 
haemorrhagic stroke in the presence of anticoagulation.  
• Prior history of falls may be a more clinically useful risk prognosticator than “risk of 
falls”.  
 
